Gavin Clark-Gartner

“I actually just wanted to ask on the earlier pipeline. So you noted in your prepared remarks that Transcon platform can fuel one IND for an NCE annually. I guess there hasn't been one yet this year.”

“Could you just help us understand the 2026 principally guidance a little more? I mean, we're sitting here in August, and it's still a fairly wide range for the course of this year.”

“First, what was this new FDA's team's rationale to conduct an additional Phase III? Like, was it more of a safety database question, or was it more around the efficacy side?”

“And just following up on the Netherton side, I guess, what are your expectations for how a placebo arm could potentially perform? Like, we have some of the Spivigo data showing a bit of an improvement from baseline.”

“I just wanted to circle back on some of the conversion metrics. So you noted that the conversion rates you're seeing are exceeding what you saw in iGAM previously. what was the rate that you saw with IGAN?”